Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

HFNO förbättrar blodsyremättnaden under asfyxi under lungkirurgi med dubbellumen endotrakeal intubation

12 november 2026 uppdaterad av: Shenzhen Second People's Hospital

Nasal syresättning med högt flöde förbättrar blodsyremättnaden under asfyxi under lungkirurgi med dubbellumen endotrakeal intubation: en randomiserad kontrollerad studie

With the continuous strengthening of the concept of rapid rehabilitation, great progress has been made in minimally invasive thoracic surgery, and thoracoscopic surgery has developed rapidly. Double-lumen endotracheal(DLT) intubation is still the most reliable way of intubation in lung surgery. However, hypoxemia faced during double-lumen intubation still threatens the perioperative safety of thoracic surgery patients. In recent years, high-flow nasal oxygenation (HFNO) has great potential in the field of anesthesia, especially playing a new and important role in the prevention and treatment of short-term hypoxia and life-threatening airway emergencies. However, the use of HFNO in pulmonary surgery patients with poor pulmonary function lacks evidence-based basis, and there are few reliable clinical data.

This study adopted a prospective, randomized, controlled, single-blind design. A total of 100 patients aged 18-60 years who underwent elective thoracoscopy-assisted pulmonary surgery were included and randomly divided into the experimental group: HFNO was used in the process of double-lumen intubation asphyxia; the control group: according to the traditional intubation process, No oxygen therapy equipment was used during intubation asphyxiation. The lowest blood oxygen saturation during intubation, the incidence of hypoxemia during intubation, perioperative complications, and postoperative hospital stay were compared between the two groups.

This study explores the advantages of HFNO in complex endotracheal intubation, assuming that HFNO can improve the oxygen saturation of double-lumen intubation; optimize the intubation method of DLT, and tap its new potential to prevent and manage emergency airway crisis.

Studieöversikt

Status

Avslutad

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Faktisk)

112

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Guangdong
      • Shenzhen, Guangdong, Kina, 518000
        • Shenzhen Second People's Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 60 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age 18-60;
  • Patients planning to undergo video-assisted thoracoscopic (VATS) lung surgery requiring DLT intubation;
  • Patients who agreed to participate in this study.

Exclusion Criteria:

  • American Society of Anesthesiologists (ASA) classification > IV;
  • Patients with severe nasal obstruction; expected difficult intubation or difficulty with mask ventilation;
  • Morbid obesity [Body Mass Index (BMI)>35kg/m2)];
  • Airway anatomical abnormalities;
  • Abnormal coagulation function;
  • Emergency surgery;
  • Patients at high risk of reflux aspiration, including ileus, full stomach, esophageal reflux disease;
  • Pregnant or breastfeeding women.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: HFNO group

Direct guidance and positioning of DLT intubation with FOB visualization, using HFNO during intubation asphyxia.

After the patient's mask-assisted ventilation makes the end-expiratory oxygen concentration (EtO2) > 90%, wear the HFNO device according to the pre-adjusted mode (temperature 34°C, oxygen concentration 100%, flow rate 50 litres per minute). The nasal cannula will remain in place until intubation is complete (including DLT intubation, direct FOB guidance, and DLT alignment with FOB). After securing the HFNO device, the glottis was exposed using a laryngoscope, and the DLT main tracheal cuff was passed through the glottis and paused under direct vision. Insert the DLT into the bronchial tube lumen of the DLT using the FOB, and then advance the DLT into the corresponding main bronchus under the guidance of the FOB. After confirming the appropriate depth of the catheter using the FOB, insert the DLT into the anesthesia machine to complete the intubation process. After the DLT was connected to the anesthesia machine and mechanical ventilation was started, the HFNO device was removed.

Andra namn:
  • högflödes nasal syrgasbehandling
Inget ingripande: Control group

The DLT cannula was directly guided and positioned under FOB visualization, and no oxygen therapy equipment was used during intubation.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Minimum blood oxygen saturation (SpO2)
Tidsram: After the DLT intubation

Minimum SpO2 measured by capillary oximeter during DLT intubation. SpO2 was continuously monitored by the monitor every 1 second and recorded every 5 seconds, and the lowest SpO2 was recorded through the monitor by the recording personnel who were not involved in anesthesia management.

After the DLT intubation

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The incidence of lowest SpO2<90%
Tidsram: After the DLT intubation

Minimum SpO2 measured by capillary oximeter during DLT intubation. SpO2 was continuously monitored by the monitor every 1 second and recorded every 5 seconds, and the lowest SpO2 was recorded through the monitor by the recording personnel who were not involved in anesthesia management.

After the DLT intubation
The incidence of lowest SpO2<95%
Tidsram: After the DLT intubation

Minimum SpO2 measured by capillary oximeter during DLT intubation. SpO2 was continuously monitored by the monitor every 1 second and recorded every 5 seconds, and the lowest SpO2 was recorded through the monitor by the recording personnel who were not involved in anesthesia management.

After the DLT intubation
DLT intubation time
Tidsram: After the DLT intubation

The DLT intubation period was defined as: from the time the video laryngoscope was placed in the oral cavity, to the confirmation of the correct position of the DLT by the FOB, and the end of the insertion of the anesthesia machine.

After the DLT intubation
End-tidal carbon dioxide partial pressure after intubation
Tidsram: After the DLT intubation

When the tracheal intubation is completed, the monitor displays the partial pressure of carbon dioxide at the end of the first mechanical ventilation.

After the DLT intubation
End-tidal oxygen concentration after intubation
Tidsram: After the DLT intubation

When the tracheal intubation is completed, the monitor displays the end-expiratory oxygen concentration of the first mechanical ventilation.

After the DLT intubation
The incidence of difficult airway
Tidsram: After the DLT intubation

Difficult airway was defined as failure of videolaryngoscope intubation, switch to fiberoptic bronchoscope-guided intubation.

After the DLT intubation
The incidence of bronchial dislocation
Tidsram: After the DLT intubation

Left or right bronchial tube strayed into right or left bronchus.

After the DLT intubation
Incidence of related complications during intubation
Tidsram: After the DLT intubation

Associated complications during intubation include: reflux aspiration, laryngospasm or bronchospasm, tracheal or bronchial tear, barotrauma, systolic blood pressure < 90 mmHg or initiation of vasoactive drugs, systolic blood pressure > 180 mmHg, severe arrhythmias, and lips or tooth damage.

After the DLT intubation
Operator satisfaction with intubation
Tidsram: After the DLT intubation

Operator satisfaction rating for intubation (range 0-10, with 0 being very dissatisfied and 10 being very satisfied).

After the DLT intubation
The incidence of low blood oxygen saturation (SpO2<90%) in the post-anaesthesia care unit (PACU)
Tidsram: Up to 1 week

After the patient entered the PACU, the blood oxygen saturation was continuously monitored and the lowest blood oxygen saturation value was recorded.

Up to 1 week
The incidence of postoperative airway-related complications
Tidsram: 1st, 2nd and 3rd day after surgery

Postoperative airway-related complications include: sore throat, hoarseness, and nasopharyngeal dryness.

1st, 2nd and 3rd day after surgery
The incidence of nausea and vomiting
Tidsram: 1st, 2nd and 3rd day after surgery

Interview patients' subjective feelings, including nausea and vomiting.

1st, 2nd and 3rd day after surgery
Patient satisfaction with anesthesia
Tidsram: The first day after surgery

Patient satisfaction with anesthesia(range 0-10, with 0 being very dissatisfied and 10 being very satisfied).

The first day after surgery
Postoperative hospital stay
Tidsram: Through study completion, an average of 4 weeks

The medical record system queries the number of days in hospital after surgery.

Through study completion, an average of 4 weeks
The incidence of postoperative complication
Tidsram: Through study completion, an average of 4 weeks

Postoperative complications included postoperative atelectasis, pneumothorax, pulmonary infection, pleural effusion, bronchopleural fistula and postoperative bleeding.

Through study completion, an average of 4 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

20 mars 2023

Primärt slutförande (Faktisk)

31 maj 2024

Avslutad studie (Faktisk)

31 maj 2024

Studieregistreringsdatum

Först inskickad

21 september 2022

Först inskickad som uppfyllde QC-kriterierna

23 december 2022

Första postat (Faktisk)

28 december 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

13 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

The research protocol will be announced later in the plan.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera